Company Description
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.
It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases.
The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Eric Easom |
Contact Details
Address: 1800 El Camino Real, Suite D Menlo Park, California 94027 United States | |
| Phone | 650 331 9090 |
| Website | an2therapeutics.com |
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| Employer ID | 82-0606654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President and Chairman of the Board |
| Joseph S. Zakrzewski | Co-Founder and Independent Chairman of the Board |
| Lucy O. Day CPA | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Joshua Eizen J.D. | Chief Legal Officer, Chief Operating Officer and Corporate Secretary |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder and Senior Clinical Advisor |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior Vice President of Research Fellow and Head of Biology |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer |
| Dr. Stephen David Prior Ph.D. | Chief Strategy Officer |
| Vince Hernandez | Senior Vice President of Research and Head of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 28, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |